Protalix BioTherapeutics, Inc. - Laporan Laba Rugi (TTM)

Protalix BioTherapeutics, Inc.
US ˙ NYSEAM ˙ US74365A3095

Laporan Laba Rugi (TTM)

Laporan Laba Rugi Protalix BioTherapeutics, Inc. menunjukkan perubahan pendapatan dan pengeluaran selama periode waktu tertentu. Data Laporan Laba Rugi meliputi Penjualan dan Pendapatan, Laba Kotor, Penelitian dan Pengembangan (R&D), Beban Penjualan, Umum dan Administrasi (SG&A), Laba Operasi, Beban Pajak Penghasilan, Beban Bunga, Pendapatan Non-Operasi, Laba per Saham (EPS), dan Saham yang Beredar.

Semua angka adalah kelipatan 1,000,000 kecuali unit per saham.

2020
09-30
2020
12-31
2021
03-31
2021
06-30
2021
09-30
2021
12-31
2022
03-31
2022
06-30
2022
09-30
2022
12-31
2023
03-31
2023
06-30
2023
09-30
2023
12-31
2024
03-31
2024
06-30
2024
09-30
2024
12-31
2025
03-31
2025
06-30
Revenue 61 63 53 48 49 38 43 45 48 48 41 67 64 65 60 38 46 53 60 62
Change (%) 2.84 -16.42 -8.64 2.63 -22.20 12.43 5.39 4.69 0.14 -13.64 63.98 -5.69 2.94 -8.92 -36.21 20.01 16.93 11.92 3.65
% of Revenue 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00
Cost Of Sales 11 11 12 15 16 16 18 17 20 20 17 19 17 23 22 26 29 24 30 26
Change (%) -1.79 12.31 23.80 5.52 2.48 7.76 -3.67 19.86 -3.69 -15.05 12.38 -11.66 39.09 -2.10 14.70 13.49 -16.97 22.94 -11.99
% of Revenue 18.10 17.29 23.23 31.47 32.36 42.63 40.86 37.35 42.76 41.13 40.45 27.72 25.97 35.09 37.72 67.82 64.14 45.54 50.03 42.47
Gross Operating Profit 50 52 40 33 33 22 25 28 27 28 24 49 47 43 37 12 16 29 30 36
Change (%) 3.86 -22.42 -18.45 1.30 -34.02 15.89 11.66 -4.36 3.01 -12.65 99.03 -3.40 -9.74 -12.60 -67.04 33.74 77.56 2.71 19.32
% of Revenue 81.90 82.71 76.77 68.53 67.64 57.37 59.14 62.65 57.24 58.87 59.55 72.28 74.03 64.91 62.28 32.18 35.86 54.46 49.97 57.53
SG&A 11 11 11 12 12 13 13 12 12 12 12 13 14 15 15 14 13 12 12 11
Change (%) -0.56 -0.44 8.80 1.14 4.22 0.13 -4.39 -0.87 -3.05 -0.33 12.17 6.28 7.51 0.00 -3.66 -7.46 -8.58 -4.20 -7.36
% of Revenue 18.33 17.72 21.11 25.14 24.78 33.19 29.56 26.81 25.39 24.58 28.37 19.41 21.87 22.84 25.08 37.87 29.20 22.83 19.55 17.47
R&D 37 38 35 33 33 30 31 31 31 29 26 23 20 17 14 13 12 13 14 17
Change (%) 3.69 -8.43 -4.28 -1.21 -10.02 5.53 -0.35 0.33 -6.45 -9.95 -11.74 -15.94 -12.83 -17.32 -10.71 -5.32 8.55 4.53 22.36
% of Revenue 60.18 60.68 66.48 69.65 67.04 77.53 72.78 68.81 65.95 61.61 64.24 34.57 30.82 26.10 23.69 33.16 26.16 24.29 22.69 26.78
OpEx 59 60 58 61 61 59 62 60 64 61 55 55 50 55 52 53 55 49 55 54
Change (%) 1.86 -3.20 4.10 0.93 -3.92 4.98 -2.13 5.58 -4.93 -9.74 0.69 -9.21 9.97 -6.26 2.42 3.29 -9.33 11.43 -2.57
% of Revenue 96.61 95.69 110.82 126.26 124.17 153.36 143.20 132.98 134.11 127.32 133.06 81.71 78.66 84.03 86.48 138.85 119.50 92.66 92.26 86.72
Operating Income 2 3 -6 -13 -12 -20 -19 -15 -16 -13 -14 12 14 10 8 -15 -9 4 5 8
Change (%) 30.85 -309.89 121.77 -5.53 71.70 -8.97 -19.55 8.27 -19.79 4.53 -190.73 10.03 -22.97 -22.92 -283.37 -39.76 -143.98 18.15 77.77
% of Revenue 3.39 4.31 -10.82 -26.26 -24.17 -53.36 -43.20 -32.98 -34.11 -27.32 -33.06 18.29 21.34 15.97 13.52 -38.85 -19.50 7.34 7.74 13.28
Interest Expense -9 -10 -7 -7 -6 -8 -6 -5 -4 -3 -3 -3 -3 -3 -3 -2 -2 -1 -1 -1
Change (%) 12.35 -30.30 2.02 -6.27 16.68 -20.45 -24.40 -20.01 -30.10 1.23 35.00 -11.57 4.06 -8.14 -39.47 3.51 -41.97 -36.16 37.61
% of Revenue -14.07 -15.38 -12.82 -14.32 -13.08 -19.61 -13.88 -9.95 -7.61 -5.31 -6.22 -5.12 -4.80 -4.86 -4.90 -4.65 -4.01 -1.99 -1.13 -1.51
Net Income -7 -7 -14 -21 -21 -28 -24 -18 -18 -15 -16 9 11 8 7 -15 -10 3 4 6
Change (%) -1.60 109.49 51.89 -1.15 34.43 -11.56 -24.22 -3.42 -16.39 5.66 -156.44 19.27 -21.70 -17.61 -314.57 -34.63 -130.52 33.29 60.57
% of Revenue -10.84 -10.37 -25.99 -43.21 -41.62 -71.92 -56.58 -40.68 -37.53 -31.33 -38.34 13.19 16.69 12.69 11.48 -38.61 -21.03 5.49 6.54 10.13

Source: Capital IQ

Other Listings
DE:PBDA € 1.30
Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista